HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology Prestigious peer-review validates HCB101’s differentiated mechanism and translational strength. Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a […] The post HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 first appeared on AsiaNewsToday.

HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 #HanchorBio #HCB101 #CD47SIRPalpha #CancerResearch #Oncology